People with congenital heart disease are seven times more likely to develop pulmonary hypertension than the general population, a long-term Danish study indicates. In addition, congenital heart disease patients with PH are four times more likely to die than those without PH, the researchers reported. Their article, “Incidence and Mortality…
Patients with higher exercise capacity present a reduced risk of pulmonary arterial hypertension-associated death or hospitalization, according to results of a Phase 3 clinical trial. The research was published in the journal PLOS One, in a study titled “Association between six-minute walk distance and long-term outcomes in patients…
Canada’s Quebec Province has agreed to provide public health insurance coverage of Actelion‘s pulmonary arterial hypertension therapy Uptravi (selexipag). The pan-Canadian Pharmaceutical Alliance (pCPA), a group that represents Canada’s provinces in trying to keep drug costs in line, played a key role in the price negotiations on Uptravi that…
Get regular updates to your inbox.